Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: Implications for genetic screening selection criteria: A Hellenic Cooperative Oncology Group Study

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 353-362

  Fostira, Florentia ^a   Tsitlaidou, Marianthi ^a   Papadimitriou, Christos ^b   Pertesi, Maroulio ^a   Timotheadou, Eleni ^c   Stavropoulou, Alexandra V ^a   Glentis, Stavros ^a   Bournakis, Evangelos ^b   Bobos, Mattheos ^c   Pectasides, Dimitrios ^d   Papakostas, Pavlos ^d   Pentheroudakis, George ^e   Gogas, Helen ^b   Skarlos, Pantelis ^f   Samantas, Epaminontas ^g   Bafaloukos, Dimitrios ^h   Kosmidis, Paris A ⁱ   Koutras, Angelos ^j   Yannoukakos, Drakoulis ^a   Konstantopoulou, Irene ^a   Fountzilas, George ^c   more..

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f Agios Savvas Cancer Hospital   (Greece)

^g AGII ANARGIRI CANCER HOSPITAL   (Greece)

^h METROPOLITAN HOSPITAL   (Greece)

ⁱ HYGEIA HOSPITAL   (Greece)

^j UNIVERSITY OF PATRAS   (Greece)

more..

Author keywords

BRCA1; Genetic testing; Hereditary breast ovarian cancer; Triple negative breast cancer

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DNA SEQUENCE; EXON; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; GREECE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; ONSET AGE; OVARY CANCER; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC TESTING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; PATIENT SELECTION; PREVALENCE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 84863984125     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2021-9     Document Type: Article

References (65)

1. JS Reis-Filho AN Tutt 2008 Triple negative tumours: a critical review Histopathology 52 1 108 118 18171422 10.1111/j.1365-2559.2007.02889.x 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D
2. WD Foulkes IE Smith JS Reis-Filho 2010 Triple-negative breast cancer N Engl J Med 363 20 1938 1948 21067385 10.1056/NEJMra1001389 1:CAS:528: DC%2BC3cXhsVCltr7P
3. WJ Irvin Jr LA Carey 2008 What is triple-negative breast cancer? Eur J Cancer 44 18 2799 2805 19008097 10.1016/j.ejca.2008.09.034 1:CAS:528: DC%2BD1cXhsVKltr%2FE
4. BP Schneider EP Winer WD Foulkes J Garber CM Perou A Richardson GW Sledge LA Carey 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 24 8010 8018 19088017 10.1158/1078-0432.CCR-08-1208 1:CAS:528:DC%2BD1cXhsV2it73F
5. F Podo LM Buydens H Degani R Hilhorst E Klipp IS Gribbestad S Van Huffel HW van Laarhoven J Luts D Monleon GJ Postma N Schneiderhan-Marra F Santoro H Wouters HG Russnes T Sørlie E Tagliabue AL Børresen-Dale FEMME Consortium 2010 Triple-negative breast cancer: present challenges and new perspectives Mol Oncol 4 3 209 229 20537966 10.1016/j.molonc.2010.04.006 1:CAS:528:DC%2BC3cXhtVGlsLvI
6. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lønning AL Børresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
7. CM Perou 2011 Molecular stratification of triple-negative breast cancers Oncologist 16 Suppl 1 61 70 21278442 10.1634/theoncologist.2011-S1-61
8. L Carey E Winer G Viale D Cameron L Gianni 2010 Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7 12 683 692 20877296 10.1038/nrclinonc.2010.154
9. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka LA Lickley E Rawlinson P Sun SA Narod 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 15 Pt 1 4429 4434 17671126 10.1158/1078-0432.CCR-06-3045
10. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 9 1721 1728 17387718 10.1002/cncr.22618
11. OI Olopade TA Grushko R Nanda D Huo 2008 Advances in breast cancer: pathways to personalized medicine Clin Cancer Res 14 24 7988 7999 19088015 10.1158/1078-0432.CCR-08-1211 1:CAS:528:DC%2BD1cXhsV2it73L
12. D Huo F Ikpatt A Khramtsov JM Dangou R Nanda J Dignam B Zhang T Grushko C Zhang O Oluwasola D Malaka S Malami A Odetunde AO Adeoye F Iyare A Falusi CM Perou OI Olopade 2009 Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer J Clin Oncol 27 27 4515 4521 19704069 10.1200/JCO.2008.19.6873 1:CAS:528:DC%2BD1MXhtlCns77P
13. KC Amirikia P Mills J Bush LA Newman 2011 Higher population-based incidence rates of triple-negative breast cancer among young African-American women : implications for breast cancer screening recommendations Cancer 117 12 2747 2753 21656753 10.1002/cncr.25862
14. MC King JH Marks JB Mandell 2003 Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 5645 643 646 14576434 10.1126/science.1088759 1:CAS:528:DC%2BD3sXotlWqt7Y%3D
15. FJ Couch 2004 Genetic epidemiology of BRCA1 Cancer Biol Ther 3 6 509 514 15254414 1:CAS:528:DC%2BD2MXhtF2kt7s%3D
16. DP Atchley CT Albarracin A Lopez V Valero CI Amos AM Gonzalez-Angulo GN Hortobagyi BK Arun 2008 Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer J Clin Oncol 26 26 4282 4288 18779615 10.1200/JCO.2008.16.6231
17. TC de Ruijter J Veeck JP de Hoon M van Engeland VC Tjan-Heijnen 2011 Characteristics of triple-negative breast cancer J Cancer Res Clin Oncol 137 2 183 192 21069385 10.1007/s00432-010-0957-x 1:CAS:528:DC%2BC3MXkt1SntA%3D%3D
18. WF Li Z Hu NY Rao CG Song B Zhang MZ Cao FX Su YS Wang PQ He GH Di KW Shen J Wu JS Lu JM Luo XY Liu J Zhou L Wang L Zhao YB Liu WT Yuan L Yang ZZ Shen W Huang ZM Shao 2008 The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified Breast Cancer Res Treat 110 1 99 109 17851763 10.1007/s10549-007-9708-3 1:CAS:528:DC%2BD1cXmslyjsrg%3D
19. A Musolino MA Bella B Bortesi M Michiara N Naldi P Zanelli M Capelletti D Pezzuolo R Camisa M Savi TM Neri A Ardizzoni 2007 BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study Breast 16 3 280 292 17257844 10.1016/j.breast.2006.12.003
20. WD Foulkes IM Stefansson PO Chappuis LR Begin JR Goffin N Wong M Trudel LA Akslen 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 19 1482 1485 14519755 10.1093/jnci/djg050 1:CAS:528:DC%2BD3sXnvVCjtrk%3D
21. SR Lakhani JS Reis-Filho L Fulford F Penault-Llorca M van der Vijver S Parry T Bishop J Benitez C Rivas YJ Bignon J Chang-Claude U Hamann CJ Cornelisse P Devilee MW Beckmann C Nestle-Krämling PA Daly N Haites J Varley F Lalloo G Evans C Maugard H Meijers-Heijboer JG Klijn E Olah BA Gusterson S Pilotti P Radice S Scherneck H Sobol J Jacquemier T Wagner J Peto MR Stratton L McGuffog DF Easton Breast Cancer Linkage Consortium 2005 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 14 5175 5180 16033833 10.1158/1078-0432.CCR-04-2424 1:CAS:528:DC%2BD2MXmt12qtbk%3D
22. NC Turner JS Reis-Filho 2006 Basal-like breast cancer and the BRCA1 phenotype Oncogene 25 43 5846 5853 16998499 10.1038/sj.onc.1209876 1:CAS:528:DC%2BD28XhtVSgurjO
23. NC Turner JS Reis-Filho AM Russell RJ Springall K Ryder D Steele K Savage CE Gillett FC Schmitt A Ashworth AN Tutt 2006 BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 14 2126 2132 17016441 10.1038/sj.onc. 1210014
24. E Alli VB Sharma P Sunderesakumar JM Ford 2009 Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase Cancer Res 69 8 3589 3596 19351835 10.1158/0008-5472.CAN-08-4016 1:CAS:528:DC%2BD1MXksV2ht7k%3D
25. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 10 814 819 15510162 10.1038/nrc1457 1:CAS:528:DC%2BD2cXos1ymu7g%3D
26. LC Collins A Martyniak MJ Kandel ZK Stadler S Masciari A Miron AL Richardson SJ Schnitt JE Garber 2009 Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers Am J Surg Pathol 33 7 1093 1097 19390427 10.1097/PAS.0b013e31819c1c93
27. SR Young RT Pilarski T Donenberg C Shapiro LS Hammond J Miller KA Brooks S Cohen B Tenenholz D Desai I Zandvakili R Royer S Li SA Narod 2009 The prevalence of BRCA1 mutations among young women with triple-negative breast cancer BMC Cancer 9 86 19298662 10.1186/1471-2407-9-86 1:CAS:528: DC%2BD1MXjvVSitLg%3D
28. AM Gonzalez-Angulo KM Timms S Liu H Chen JK Litton J Potter JS Lanchbury K Stemke-Hale BT Hennessy BK Arun GN Hortobagyi KA Do GB Mills F Meric-Bernstam 2011 Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer Clin Cancer Res 17 5 1082 1089 21233401 10.1158/1078-0432.CCR-10-2560 1:CAS:528:DC%2BC3MXis1eisbc%3D
29. DG Evans A Howell D Ward F Lalloo JL Jones DM Eccles 2011 Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer J Med Genet 48 8 520 522 21653198 10.1136/jmedgenet-2011-100006 1:STN:280:DC%2BC3MnpvF2nsQ%3D%3D
30. E Comen M Davids T Kirchhoff C Hudis K Offit M Robson 2011 Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women Breast Cancer Res Treat 129 1 185 190 21394499 10.1007/s10549-011-1433-2 1:CAS:528:DC%2BC3MXptVOitro%3D
31. I Konstantopoulou T Rampias A Ladopoulou G Koutsodontis S Armaou T Anagnostopoulos G Nikolopoulos S Kamakari G Nounesis A Stylianakis C Karanikiotis E Razis H Gogas A Keramopoulos V Gaki C Markopoulos D Skarlos N Pandis T Bei I Arzimanoglou G Fountzilas D Yannoukakos 2008 Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients Breast Cancer Res Treat 107 3 431 441 17453335 10.1007/s10549-007-9571-2 1:CAS:528:DC%2BD1cXht1Sgsbk%3D
32. S Armaou M Pertesi F Fostira G Thodi PS Athanasopoulos S Kamakari A Athanasiou H Gogas D Yannoukakos G Fountzilas I Konstantopoulou 2009 Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases Br J Cancer 101 1 32 37 19491894 10.1038/sj.bjc.6605115 1:CAS:528:DC%2BD1MXotVKgtbs%3D
33. G Fountzilas D Skarlos U Dafni H Gogas E Briasoulis D Pectasides C Papadimitriou C Markopoulos A Polychronis HP Kalofonos V Siafaka P Kosmidis E Timotheadou D Tsavdaridis D Bafaloukos P Papakostas E Razis P Makrantonakis G Aravantinos C Christodoulou AM Dimopoulos 2005 Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 16 11 1762 1771 16148021 10.1093/annonc/mdi366 1:STN:280:DC%2BD2MrlvFGlsw%3D%3D
34. G Fountzilas U Dafni H Gogas H Linardou HP Kalofonos E Briasoulis D Pectasides E Samantas D Bafaloukos GP Stathopoulos M Karina C Papadimitriou D Skarlos N Pisanidis P Papakostas C Markopoulos E Tzorakoeleftherakis K Dimitrakakis P Makrantonakis N Xiros A Polichronis I Varthalitis C Karanikiotis AM Dimopoulos Hellenic Cooperative Oncology Group 2008 Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 Ann Oncol 19 5 853 860 18042835 10.1093/annonc/mdm539 1:STN:280:DC%2BD1c3nvV2qtA%3D%3D
35. G Fountzilas D Pectasides C Christodoulou E Timotheadou T Economopoulos P Papakostas C Papadimitriou H Gogas I Efstratiou D Skarlos 2006 Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer Med Oncol 23 4 479 488 17303906 10.1385/MO:23:4:479 1:CAS:528:DC%2BD2sXht1antLs%3D
36. CA Papadimitriou P Papakostas E Timotheadou G Aravantinos A Bamias G Fountzilas 2008 Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study Cancer Invest 26 5 491 498 18568771 10.1080/07357900701829785 1:CAS:528:DC%2BD1cXnsFejtL4%3D
37. G Fountzilas U Dafni MA Dimopoulos A Koutras D Skarlos P Papakostas H Gogas D Bafaloukos A Kalogera-Fountzila E Samantas E Briasoulis D Pectasides N Maniadakis F Matsiakou G Aravantinos C Papadimitriou M Karina C Christodoulou P Kosmidis HP Kalofonos 2009 A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study Breast Cancer Res Treat 115 1 87 99 18483853 10.1007/s10549-008-0047-9 1:CAS:528:DC%2BD1MXkvVyqsr0%3D
38. D Pectasides V Kotoula H Fountzilas I Korantzis A Koutras AM Dimopoulos P Papakostas G Aravantinos I Varthalitis P Kosmidis D Skarlos E Bournakis D Bafaloukos HP Kalofonos KT Kalogeras G Fountzilas 2011 Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) study Oncol Rep 27 1 216 224 22025320
39. G Fountzilas HP Kourea M Bobos D Televantou V Kotoula C Papadimitriou KT Papazisis E Timotheadou I Efstratiou A Koutras G Pentheroudakis C Christodoulou G Aravantinos D Miliaras K Petraki CN Papandreou P Papakostas D Bafaloukos D Repana E Razis D Pectasides AM Dimopoulos 2011 Paclitaxel and bevacizumab, as first line combined treatment, in patients with metastatic breast cancer. The Hellenic Cooperative Oncology Group experience with biological marker evaluation Anticancer Res 31 9 3007 3018 21868552 1:CAS:528:DC%2BC3MXhtFSls7vM
40. SA Miller DD Dykes HF Polesky 1988 A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res 16 3 1215 3344216 10.1093/nar/16.3.1215 1:CAS:528:DyaL1cXhsVKlsrs%3D
41. S Armaou I Konstantopoulou T Anagnostopoulos E Razis I Boukovinas N Xenidis G Fountzilas D Yannoukakos 2007 Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients Eur J Cancer 43 2 443 453 17174087 10.1016/j.ejca.2006.09.021 1:CAS:528:DC%2BD2sXpvVKqsA%3D%3D
42. A Goldhirsch JN Ingle RD Gelber AS Coates B Thurlimann HJ Senn 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 8 1319 1329 19535820 10.1093/annonc/mdp322 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D
43. EA Rakha ME El-Sayed AR Green AH Lee JF Robertson IO Ellis 2007 Prognostic markers in triple-negative breast cancer Cancer 109 1 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D
44. MC Cheang D Voduc C Bajdik S Leung S McKinney SK Chia CM Perou TO Nielsen 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 5 1368 1376 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D
45. TS Frank AM Deffenbaugh JE Reid M Hulick BE Ward B Lingenfelter KL Gumpper T Scholl SV Tavtigian DR Pruss GC Critchfield 2002 Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals J Clin Oncol 20 6 1480 1490 11896095 10.1200/JCO.20.6.1480 1:CAS:528:DC%2BD38XivFeisbY%3D
46. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996 (1996) J Clin Oncol 14(5):1730-1736 (discussion 1737-1740)
47. DM Euhus KC Smith L Robinson A Stucky OI Olopade S Cummings JE Garber A Chittenden GB Mills P Rieger L Esserman B Crawford KS Hughes CA Roche PA Ganz J Seldon CJ Fabian J Klemp G Tomlinson 2002 Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO J Natl Cancer Inst 94 11 844 851 12048272 10.1093/jnci/94.11.844 1:CAS:528:DC%2BD38Xlt1Sqs70%3D
48. D Gadzicki DG Evans H Harris C Julian-Reynier I Nippert J Schmidtke A Tibben CJ van Asperen B Schlegelberger 2011 Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany J Community Genet 2 2 53 69 22109790 10.1007/s12687-011-0042-4
49. JS Kwon AM Gutierrez-Barrera D Young CC Sun MS Daniels KH Lu B Arun 2010 Expanding the criteria for BRCA mutation testing in breast cancer survivors J Clin Oncol 28 27 4214 4220 20733129 10.1200/JCO.2010.28.0719
50. Breast Cancer Linkage Consortium 1997 Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases Lancet 349 9064 1505 1510 10.1016/S0140-6736(96) 10109-4
51. F Eisinger J Jacquemier C Charpin D Stoppa-Lyonnet B Bressac-de Paillerets JP Peyrat M Longy JM Guinebretiere R Sauvan T Noguchi D Birnbaum H Sobol 1998 Mutations at BRCA1: the medullary breast carcinoma revisited Cancer Res 58 8 1588 1592 9563465 1:CAS:528:DyaK1cXislertLw%3D
52. P Tisserand C Fouquet M Barrois C Gallou R Dendale D Stoppa-Lyonnet X Sastre-Garau A Fourquet T Soussi 2003 Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors Cancer Biol Ther 2 5 559 563 14614327 1:CAS:528: DC%2BD2cXhtVOiu78%3D
53. L Da Silva SR Lakhani 2010 Pathology of hereditary breast cancer Mod Pathol 23 Suppl 2 S46 S51 20436502 10.1038/modpathol.2010.37
54. PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink P Mortimer H Swaisland A Lau MJ O'Connor A Ashworth J Carmichael SB Kaye JH Schellens J de Bono 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 123 134 19553641 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D
55. J O'Shaughnessy C Osborne JE Pippen M Yoffe D Patt C Rocha IC Koo BM Sherman C Bradley 2011 Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 3 205 214 21208101 10.1056/NEJMoa1011418
56. SK Pal BH Childs M Pegram 2011 Triple negative breast cancer: unmet medical needs Breast Cancer Res Treat 125 3 627 636 21161370 10.1007/s10549-010-1293-1 1:CAS:528:DC%2BC3MXhtVelsbw%3D
57. M Guha 2011 PARP inhibitors stumble in breast cancer Nat Biotechnol 29 5 373 374 21552220 10.1038/nbt0511-373 1:CAS:528:DC%2BC3MXlslyku7c%3D
58. T Byrski J Gronwald T Huzarski E Grzybowska M Budryk M Stawicka T Mierzwa M Szwiec R Wisniowski M Siolek R Dent J Lubinski S Narod 2010 Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy J Clin Oncol 28 3 375 379 20008645 10.1200/JCO.2008.20. 7019 1:CAS:528:DC%2BC3cXivFart74%3D
59. JS de Bono A Ashworth 2010 Translating cancer research into targeted therapeutics Nature 467 7315 543 549 20882008 10.1038/nature09339
60. T Anagnostopoulos M Pertesi I Konstantopoulou S Armaou S Kamakari G Nasioulas A Dobrovic MA Young G Mitchell G Fountzilas D Yannoukakos 2008 A novel BRCA1 founder mutation G1738R related to breast-ovarian cancer predisposition, found in Greek patients Breast Cancer Res Treat 110 2 377 385 17902052 10.1007/s10549-007-9729-y 1:CAS:528:DC%2BD1cXmslyhu7Y%3D
61. M Pertesi I Konstantopoulou D Yannoukakos 2011 Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests that they are founder mutations for the Greek population Clin Genet 80 375 382 10.1111/j.1399-0004.2010.01532.x 1:CAS:528:DC%2BC3MXhtlans7fE
62. A Petrij-Bosch T Peelen M van Vliet R van Eijk R Olmer M Drüsedau FB Hogervorst S Hageman PJ Arts MJ Ligtenberg H Meijers-Heijboer JG Klijn HF Vasen CJ Cornelisse LJ van 't Veer E Bakker GJ van Ommen P van Devilee 1997 BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients Nat Genet 17 3 341 345 9354803 10.1038/ng1197-341 1:CAS:528:DyaK2sXntVSqtLk%3D
63. Α Ladopoulou Ι Konstantopoulou S Armaou E Efstathiou M Mihalatos G Bardi G Nasioulas N Pandis D Yannoukakos 2002 A change in the last base of BRCA1 exon 23, 5586G>A, results in abnormal RNA splicing Cancer Genet Cytogenet 134 2 175 177 12034536 10.1016/S0165-4608(01)00623-9 1:CAS:528:DC%2BD38XktVClsbw%3D
64. MD Sluiter EJ van Rensburg 2011 Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation Breast Cancer Res Treat 125 2 325 349 20232141 10.1007/s10549-010-0817-z 1:CAS:528:DC%2BC3cXhsFCqt7%2FF
65. BG Haffty Q Yang M Reiss T Kearney SA Higgins J Weidhaas L Harris W Hait D Toppmeyer 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 36 5652 5657 17116942 10.1200/JCO.2006.06.5664